Drug Manufacturers – Other

(PCYC) Synageva BioPharma Candidate Earns FDA Breakthrough Therapy Designation

Synageva BioPharma Corp. (GEVA) recently announced that it has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for sebelipase alfa.

Synageva is developing sebelipase alfa for the treatment...

19Aug2013 | | Comments Off on (PCYC) Synageva BioPharma Candidate Earns FDA Breakthrough Therapy Designation | Continued

(NVO) Novo Nordisk’s N9-GP See Positive Test Results

Novo Nordisk (NVO) recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study.

Paradigm 2 evaluated N9-GP, a long-acting FIX derivative, for on-demand or prophylactic treatment...

19Aug2013 | | Comments Off on (NVO) Novo Nordisk’s N9-GP See Positive Test Results | Continued

(UTHR) Bayer Files Riociguat in Japan

The HealthCare segment of Bayer (BAYRY) recently submitted a regulatory application for its chronic thromboembolic pulmonary hypertension (CTEPH) candidate, riociguat, in Japan.

Bayer mentioned in its press release that riociguat...

19Jul2013 | | Comments Off on (UTHR) Bayer Files Riociguat in Japan | Continued

(VRX) Valeant Pharmaceuticals Beats Earnings – Misses Revenues

Valeant Pharmaceuticals’ (VRX) first quarter 2013 earnings of $1.27 (excluding special items but including stock-based compensation expense) were short of the Zacks Consensus Estimate by a penny but were up from the year-ago earnings...

16May2013 | | Comments Off on (VRX) Valeant Pharmaceuticals Beats Earnings – Misses Revenues | Continued

(NVO) Novo Nordisk A/S – Emisphere Technologies Modify Deal

Novo Nordisk A/S (NVO) and Emisphere Technologies, Inc. (EMIS) recently announced that they have modified their agreement for the development and commercialization...

16May2013 | | Comments Off on (NVO) Novo Nordisk A/S – Emisphere Technologies Modify Deal | Continued

(ENDP) Endo Health Solutions Sees FDA Setback on Opana ER

Endo Health Solutions Inc. (ENDP) recently suffered a setback with the US Food and Drug Administration (FDA) turning down its request to prevent the entry of generic versions of the company’s painkiller Opana ER.

We remind...

15May2013 | | Comments Off on (ENDP) Endo Health Solutions Sees FDA Setback on Opana ER | Continued

(FRX) Forest Laboratories Sees Positive Data on Combo Drug

Forest Laboratories, Inc. (FRX) and Almirall, S.A. recently announced positive top-line data on their chronic obstructive pulmonary disease (COPD) fixed dose combination candidate, aclidinium bromide (LAMA) and formoterol fumarate...

7May2013 | | Comments Off on (FRX) Forest Laboratories Sees Positive Data on Combo Drug | Continued

(MDCO) The Medicines Company Earnings Increase

The Medicines Company (MDCO) reported first quarter earnings of 24 cents per share, compared with the year-ago earnings of 14 cents per share.

Including one-time items, the company reported a loss of 21 cents per share compared...

29Apr2013 | | Comments Off on (MDCO) The Medicines Company Earnings Increase | Continued

(VRTX) Actelion Beats Earnings – Sales Rise

Actelion Ltd. (ALIOF) reported first quarter 2013 earnings of $1.35 per American Depository Receipt (ADR), up 56.1% from the prior-year earnings of 87 cents per ADR. Earnings were well above the Zacks Consensus Estimate...

27Apr2013 | | Comments Off on (VRTX) Actelion Beats Earnings – Sales Rise | Continued

(WCRX) Warner Chilcott Earns Good News from US Food and Drug Administration

Warner Chilcott plc (WCRX) recently received encouraging news from the US Food and Drug Administration (FDA) when the regulatory agency approved the company’s acne drug Doryx at 200 mg strength (delayed release tablets). The company...

23Apr2013 | | Comments Off on (WCRX) Warner Chilcott Earns Good News from US Food and Drug Administration | Continued

(UTHR) United Therapeutics Corporation to Move Pluristem Therapeutics Drug into Phase I

United Therapeutics Corporation (UTHR) recently gained approval for the commencement of a phase I study in Australia using Pluristem Therapeutics Inc.’s (PSTI)...

21Apr2013 | | Comments Off on (UTHR) United Therapeutics Corporation to Move Pluristem Therapeutics Drug into Phase I | Continued

(PCYC) Pharmacyclics Earns 4th Milestone

Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase III study, RESONATE-2, which is being conducted to evaluate ibrutinib as a monotherapy versus chlorambucil in elderly patients...

21Apr2013 | | Comments Off on (PCYC) Pharmacyclics Earns 4th Milestone | Continued

(ENDP) Actavis Files ANDA for Endo Health Solutions Product

Actavis, Inc. (ACT) recently announced that it is looking to get its generic version of Endo Health Solutions Inc.’s (ENDP) Fortesta (testosterone gel 10mg/0.5g)...

6Mar2013 | | Comments Off on (ENDP) Actavis Files ANDA for Endo Health Solutions Product | Continued

(LCI) UCB In-licenses Parkinson’s Drug

UCB (UCBJF) recently announced that it has licensed exclusive global rights to tozadenant (SYN115) for Parkinson’s disease from Biotie Therapies.

The Candidate

Tozadenant is an orally administered, selective inhibitor...

5Mar2013 | | Comments Off on (LCI) UCB In-licenses Parkinson’s Drug | Continued

(CBST) Cubist Pharmaceuticals Sees Encouraging News From FDA

Recently, Cubist Pharmaceuticals Inc. (CBST) received some encouraging news when the US Food and Drug Administration (FDA) designated its antibiotic candidate CXA-201 (ceftolozane/tazobactam) as a qualified infectious disease product...

5Mar2013 | | Comments Off on (CBST) Cubist Pharmaceuticals Sees Encouraging News From FDA | Continued

(AGN) Allergan Earnings Miss but Guidance Tops

Allergan, Inc. (AGN) reported fourth quarter 2012 earnings of $1.15 per share, missing the Zacks Consensus Estimate of $1.19 per share.

While earnings increased 15.0% from the year-ago quarter, revenues increased 7.6% to $1,508.9...

24Feb2013 | | Comments Off on (AGN) Allergan Earnings Miss but Guidance Tops | Continued

(AMRN) Amarin Corporation Aims to Fortify Vascepa Patent

Amarin Corporation plc (AMRN), recently announced that the notice of patent allowance for US application serial number 13/610,217 has been published by the US Patent and Trademark Office (USPTO). The patent application aims to protect...

23Jan2013 | | Comments Off on (AMRN) Amarin Corporation Aims to Fortify Vascepa Patent | Continued

(ARQL) ArQule Shares Fall on Oncology Drug Candidate Setback

ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated ArQule’s lead pipeline candidate, tivantinib, in combination with...

16Jan2013 | | Comments Off on (ARQL) ArQule Shares Fall on Oncology Drug Candidate Setback | Continued

(GERN) Geron’s Update on Stem Cell Assets

Geron Corporation (GERN) announced that it has signed an Asset Contribution Agreement with BioTime, Inc. (BTX) and BioTime’s recently formed subsidiary, BioTime...

16Jan2013 | | Comments Off on (GERN) Geron’s Update on Stem Cell Assets | Continued

(MDCO) The Medicines Company Sees Positive Results on Cangrelor

The Medicines Company (MDCO) recently received good news with the company announcing positive results on its phase III candidate, cangrelor. Cangrelor is being developed for the prevention of platelet activation and aggregation that...

15Jan2013 | | Comments Off on (MDCO) The Medicines Company Sees Positive Results on Cangrelor | Continued

(OREX) Orexigen Therapeutics Provides Update on Obesity Drug Candidate

Orexigen Therapeutics, Inc. (OREX) recently provided an update on its obesity candidate, Contrave. The company, which had received a complete response letter (CRL) from the US Food and Drug Administration (FDA) in Jan 2011 for Contrave,...

15Jan2013 | | Comments Off on (OREX) Orexigen Therapeutics Provides Update on Obesity Drug Candidate | Continued

(UTHR) United Therapeutics Reiterated at Neutral

We recently reiterated a Neutral recommendation on United Therapeutics (UTHR).

While the company reported strong third-quarter results, United Therapeutics suffered a major blow in October with the US Food and Drug Administration...

2Jan2013 | | Comments Off on (UTHR) United Therapeutics Reiterated at Neutral | Continued

(FRX) Synergy Pharmaceuticals Shows Pipeline Progress

Synergy Pharmaceuticals (SGYP) recently initiated a phase IIb study with plecanatide for the treatment of patients suffering from constipation-predominant irritable bowel syndrome (IBS-C).

Synergy Pharma will be enrolling 350...

1Jan2013 | | Comments Off on (FRX) Synergy Pharmaceuticals Shows Pipeline Progress | Continued

(NVO) Novo Nordisk’s Ryzodeg Approved in Japan

Denmark based Novo Nordisk (NVO) recently announced that it has received approval in Japan for its diabetes treatment, Ryzodeg (insulin degludec/insulin aspart).
Ryzodeg was submitted for regulatory approval...

1Jan2013 | | Comments Off on (NVO) Novo Nordisk’s Ryzodeg Approved in Japan | Continued

(MDCO) The Medicines Company Strikes Two Deals

The Medicines Company (MDCO) recently signed two agreements in a bid to boost its top line. While one agreement relates to the in-licensing of a product, the other is an acquisition deal. Both deals will see the company making upfront...

23Dec2012 | | Comments Off on (MDCO) The Medicines Company Strikes Two Deals | Continued

(ISIS) Isis Pharmaceuticals and AstraZeneca Ink Deal

Isis Pharmaceuticals Inc. (ISIS) and AstraZeneca (AZN) recently announced that they have entered into an agreement to discover and develop five new generation antisense...

16Dec2012 | | Comments Off on (ISIS) Isis Pharmaceuticals and AstraZeneca Ink Deal | Continued

(VRTX) Vertex Pharmaceuticals Posts Disappointing Quarter

Vertex Pharmaceuticals Inc. (VRTX) posted break-even (including stock-based compensation expense) results in the third quarter of 2012, well below the year-ago earnings of 56 cents per share. Third quarter results missed the Zacks...

24Nov2012 | | Comments Off on (VRTX) Vertex Pharmaceuticals Posts Disappointing Quarter | Continued

(ARNA) Arena Pharmaceuticals Initiates PAH Study

Arena Pharmaceuticals, Inc. (ARNA) recently initiated a phase I multiple dose study with APD811, which is being developed for the treatment of pulmonary arterial hypertension (PAH).

Arena Pharma is expecting to enroll 30 healthy...

23Oct2012 | | Comments Off on (ARNA) Arena Pharmaceuticals Initiates PAH Study | Continued

(ISIS) Isis Pharmaceuticals Owns 18% of Regulus

Isis Pharmaceuticals, Inc. (ISIS) recently announced that it has invested $3 million in biopharma company Regulus Therapeutics Inc.’s (RGLS) common stock at the...

14Oct2012 | | Comments Off on (ISIS) Isis Pharmaceuticals Owns 18% of Regulus | Continued

(TEVA) Teva Pharmaceutical Industries Acquires Huntington Candidate

Teva Pharmaceutical Industries Ltd (TEVA) recently announced a deal that will expand the company’s central nervous system (CNS) pipeline. Teva acquired all rights, assets and obligations relating to Huntexil (pridopidine / ACR16)...

10Oct2012 | | Comments Off on (TEVA) Teva Pharmaceutical Industries Acquires Huntington Candidate | Continued